SynthesisFrontiers in immunology2026
Effect of budesonide oral suspension on dysphagia and esophageal inflammation in eosinophilic esophagitis: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated esophageal disease defined by the combination of clinical symptoms of esophageal dysfunction and histological evidence of eosinophilic infiltration (≥15 eosinophils per high-power field [eos/hpf]) once secondary causes have been excluded. Tissue remodelling and impaired motility cause dysphagia and food impaction. Budesonide oral suspension (BOS) is a topical corticosteroid formulated to enhance mucosal contact and reduce inflammation. This systematic review and meta-analysis evaluated the efficacy and safety of BOS in improving dysphagia and achieving histological remission in EoE. Methods: Following the PRISMA 2020 statement, PubMed, Scopus, Web of Science, and EMBASE were searched from inception to October 14, 2024, with an update verified up to the date of submission. Randomized controlled trials (RCTs) comparing BOS (1-2 mg twice daily) versus placebo in pediatric or adult EoE patients treated for ≥12 weeks were included. The primary outcome was histologic remission (<15 eos/hpf). Secondary outcomes included endoscopic findings (Eosinophilic Esophagitis Endoscopic Reference Score, EREFS), patient-reported symptom severity (assessed with validated symptom instruments, including the Dysphagia Symptom Questionnaire, DSQ), and treatment-emergent adverse events. Random-effects meta-analyses were performed using the Paule-Mandel estimator, and certainty of evidence was graded with GRADE. Mean difference (MD; the average between-group difference in the unit of the outcome) and odds ratio (OR) were reported with 95% confidence intervals (CI). Results: Four RCTs (n = 523) met the inclusion criteria. BOS significantly improved histologic outcomes versus placebo (MD = -54.62 eos/hpf; 95% CI -68.19 to -41.05; I Conclusions: BOS effectively reduces esophageal inflammation and alleviates dysphagia in EoE, supporting its use as a first-line topical therapy. The novel contribution of this synthesis is a strictly homogenous BOS-versus-placebo evidence base in which formulation, dose range, and follow-up are aligned across the four RCTs, complementing-rather than duplicating-broader meta-analyses that pooled heterogeneous budesonide preparations. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42025631228, identifier CRD4202525631228.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.